In this regard, we are evaluating the effects of inhibiting uPA in a clinically representative orthotopic mouse model (early and advanced) of PDAC in both immune-deficient and immune-competent (syngeneic KPC model, where a mixture of mouse cancer cells and mouse pancreatic stellate cells is implanted into the KPC mouse pancreas) settings with more numbers of mice. This evidence concerns the gene PLAU and cancer.